论文部分内容阅读
目的探讨在孕早期用血清Nesfatin-1、RBP-4检测,来预测妊娠期糖尿病(GDM)的临床效果。方法选取2015年6月—2017年1月在该院建档并行孕早期(11~13周)检查的390例孕妇,均于孕早期及孕中期测量研究对象身高、体重,计算体质量指数(BMI),同时抽取受检者空腹静脉血,检测血清Nesfatin-1、RBP-4及空腹血糖水平。孕中期行75 g OGTT检查,确诊188例孕妇为GDM组,202例糖代谢正常孕妇设为对照组。对比GDM组及对照组一般情况(年龄、孕周、BMI、空腹血糖)、血清Nesfatin-1、RBP-4水平,同时对比GDM组不同孕期血清Nesfatin-1、RBP-4水平,分析血清Nesfatin-1、RBP-4与GDM的相关性。结果 GDM组血清Nesfatin-1、RBP-4的测定值均高于对照组(P<0.01),差异有统计学意义。结论孕早期检测血清Nesfatin-1、RBP-4,对GDM早期诊断有重要的临床价值。
Objective To investigate the clinical efficacy of serum Nesfatin-1 and RBP-4 in early pregnancy to predict gestational diabetes mellitus (GDM). Methods 390 pregnant women who were examined in the first trimester of pregnancy (11 ~ 13 weeks) were enrolled in this hospital from June 2015 to January 2017. The height and weight of the study objects were measured in the first trimester and the second trimester. The body mass index BMI). Fasting venous blood was collected from the subjects and serum levels of Nesfatin-1, RBP-4 and fasting blood glucose were measured. In the second trimester, 75 g OGTT was performed, and 188 pregnant women were diagnosed as GDM group. 202 pregnant women with normal glucose metabolism were assigned as control group. The levels of Nesfatin-1 and RBP-4 in GDM group were compared with those in GDM group and normal control group (age, gestational age, BMI, fasting blood glucose), serum Nesfatin-1 and RBP- 1, RBP-4 and GDM relevance. Results The serum levels of Nesfatin-1 and RBP-4 in GDM group were significantly higher than those in control group (P <0.01). The difference was statistically significant. Conclusion The detection of serum Nesfatin-1 and RBP-4 in early pregnancy has important clinical value in the early diagnosis of GDM.